460 Stock Overview
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.59|
|52 Week High||HK$3.95|
|52 Week Low||HK$0.92|
|1 Month Change||20.46%|
|3 Month Change||-6.47%|
|1 Year Change||20.46%|
|3 Year Change||0%|
|5 Year Change||-30.87%|
|Change since IPO||-44.89%|
Recent News & Updates
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Does the November share price for Sihuan Pharmaceutical Holdings Group Ltd. ( HKG:460 ) reflect what it's really worth...
Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|460||HK Pharmaceuticals||HK Market|
Return vs Industry: 460 exceeded the Hong Kong Pharmaceuticals industry which returned -20.6% over the past year.
Return vs Market: 460 exceeded the Hong Kong Market which returned -16% over the past year.
|460 Average Weekly Movement||8.5%|
|Pharmaceuticals Industry Average Movement||6.7%|
|Market Average Movement||6.7%|
|10% most volatile stocks in HK Market||13.2%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 460 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 460's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebral vascular system, digestive system, metabolism, anti-infective, respiratory, neurology, and other drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials and medical instruments; project preparation for the manufacture of pharmaceutical products; promotion of technology, biotechnology, and consulting services; and construction of medical projects, as well as the provision of information support, research and development, business and development, and general hospital and hospital management services.
Sihuan Pharmaceutical Holdings Group Fundamentals Summary
|460 fundamental statistics|
Is 460 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|460 income statement (TTM)|
|Cost of Revenue||CN¥721.39m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.10|
|Net Profit Margin||28.50%|
How did 460 perform over the long term?See historical performance and comparison
Is Sihuan Pharmaceutical Holdings Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 460 (HK$1.59) is trading below our estimate of fair value (HK$1.87)
Significantly Below Fair Value: 460 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 460 is poor value based on its PE Ratio (12.8x) compared to the Hong Kong Pharmaceuticals industry average (9.8x).
PE vs Market: 460 is poor value based on its PE Ratio (12.8x) compared to the Hong Kong market (9.1x).
Price to Earnings Growth Ratio
PEG Ratio: 460 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 460 is overvalued based on its PB Ratio (1.2x) compared to the HK Pharmaceuticals industry average (1.1x).
How is Sihuan Pharmaceutical Holdings Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 460's forecast earnings growth (22.8% per year) is above the savings rate (1.5%).
Earnings vs Market: 460's earnings (22.8% per year) are forecast to grow faster than the Hong Kong market (16.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 460's revenue (20.5% per year) is forecast to grow faster than the Hong Kong market (11.7% per year).
High Growth Revenue: 460's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 460's Return on Equity is forecast to be low in 3 years time (18.2%).
How has Sihuan Pharmaceutical Holdings Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 460 has a large one-off gain of CN¥217.5M impacting its June 30 2021 financial results.
Growing Profit Margin: 460 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 460's earnings have declined by 38.3% per year over the past 5 years.
Accelerating Growth: 460 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 460 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).
Return on Equity
High ROE: 460's Return on Equity (9.1%) is considered low.
How is Sihuan Pharmaceutical Holdings Group's financial position?
Financial Position Analysis
Short Term Liabilities: 460's short term assets (CN¥7.2B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 460's short term assets (CN¥7.2B) exceed its long term liabilities (CN¥1.0B).
Debt to Equity History and Analysis
Debt Level: 460 has more cash than its total debt.
Reducing Debt: 460's debt to equity ratio has increased from 0.07% to 7.6% over the past 5 years.
Debt Coverage: 460's debt is well covered by operating cash flow (100.4%).
Interest Coverage: 460 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Sihuan Pharmaceutical Holdings Group current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 460's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 460's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 460's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 460's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 460 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 460's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Weicheng Guo (57 yo)
Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...
CEO Compensation Analysis
Compensation vs Market: Weicheng's total compensation ($USD944.44K) is above average for companies of similar size in the Hong Kong market ($USD480.15K).
Compensation vs Earnings: Weicheng's compensation has been consistent with company performance over the past year.
Experienced Management: 460's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: 460's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sihuan Pharmaceutical Holdings Group Ltd.'s employee growth, exchange listings and data sources
- Name: Sihuan Pharmaceutical Holdings Group Ltd.
- Ticker: 460
- Exchange: SEHK
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$14.835b
- Shares outstanding: 9.33b
- Website: https://www.sihuanpharm.com
Number of Employees
- Sihuan Pharmaceutical Holdings Group Ltd.
- Convention Plaza
- Room 4309, Office Tower
- Wan Chai
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 15:46|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.